TY - JOUR
T1 - A reduced dose of darunavir/ritonavir is effective in PI-experienced HIV-infected patients
AU - Lanzafame, Massimiliano
AU - Bonora, Stefano
AU - Lattuada, Emanuela
AU - Calcagno, Andrea
AU - Vento, Sandro
PY - 2011/9
Y1 - 2011/9
N2 - Darunavir (DRV) is an HIV-1 protease inhibitor that is used together with a low boosting dose of ritonavir as part of an antiretroviral therapy (ART) regimen in treatment-experienced and naïve HIVpositive patients. In naïve and experienced patients with no DRV-mutations, DRV is licensed at the dose of 800 mg plus 100 mg of ritonavir once daily. We report our results in seven ART-experienced HIV-infected patients, in whom a reduced dose of darunavir/ritonavir (600/100 mg once daily) successfully controlled viral replication.
AB - Darunavir (DRV) is an HIV-1 protease inhibitor that is used together with a low boosting dose of ritonavir as part of an antiretroviral therapy (ART) regimen in treatment-experienced and naïve HIVpositive patients. In naïve and experienced patients with no DRV-mutations, DRV is licensed at the dose of 800 mg plus 100 mg of ritonavir once daily. We report our results in seven ART-experienced HIV-infected patients, in whom a reduced dose of darunavir/ritonavir (600/100 mg once daily) successfully controlled viral replication.
KW - HIV infections
KW - Pharmacokinetics antiretroviral therapy, highly active
UR - http://www.scopus.com/inward/record.url?scp=82855181516&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=82855181516&partnerID=8YFLogxK
U2 - 10.1016/S1413-8670(11)70237-9
DO - 10.1016/S1413-8670(11)70237-9
M3 - Letter
C2 - 22230862
AN - SCOPUS:82855181516
SN - 1413-8670
VL - 15
SP - 498
EP - 500
JO - Brazilian Journal of Infectious Diseases
JF - Brazilian Journal of Infectious Diseases
IS - 5
ER -